Guidelines for Clinical Management of Patients with Sickle Cell Disease in Canada

Unclear health insurance coverage is a daunting reality for thousands of international students yearly.

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Impact of systemic racism on black communities, healthcare, and sickle cell disease.

Addressing the health equity gap for individuals with sickle cell disease in Ontario, Canada.

A black History Month address to the community, from Founder & CEO Mrs. Lanre Tunji-Ajayi.

Breathing plays an essential role in our well-being. Follow the advice of Dr. Marie.